PT - JOURNAL ARTICLE AU - Corinne M. Hohl AU - Rhonda J. Rosychuk AU - Jeffrey P. Hau AU - Jake Hayward AU - Megan Landes AU - Justin W. Yan AU - Daniel K. Ting AU - Michelle Welsford AU - Patrick M Archambault AU - Eric Mercier AU - Kavish Chandra AU - Philip Davis AU - Samuel Vaillancourt AU - Murdoch Leeies AU - Serena Small AU - Laurie J. Morrison AU - on behalf of the Canadian COVID-19 Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Researchers and for the Canadian Critical Care Trials Group TI - TREATMENTS, RESOURCE UTILIZATION, AND OUTCOMES OF COVID-19 PATIENTS PRESENTING TO EMERGENCY DEPARTMENTS ACROSS PANDEMIC WAVES: AN OBSERVATIONAL STUDY BY THE CANADIAN COVID-19 EMERGENCY DEPARTMENT RAPID RESPONSE NETWORK (CCEDRRN) AID - 10.1101/2021.07.30.21261288 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.30.21261288 4099 - http://medrxiv.org/content/early/2021/08/01/2021.07.30.21261288.short 4100 - http://medrxiv.org/content/early/2021/08/01/2021.07.30.21261288.full AB - Background Treatment strategies for coronavirus disease 2019 (COVID-19) evolved between pandemic waves. Our objective was to compare treatments, acute care resource utilization, and outcomes of COVID-19 patients presenting to Emergency Departments across two pandemic waves.Methods This observational study enrolled consecutive eligible COVID-19 patients presenting to 46 Emergency Departments participating in the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) between March 1 and December 31, 2020. We collected data by retrospective chart review. Our primary outcome was in-hospital mortality. We used logistic regression modeling to assess the impact of pandemic wave on outcomes.Results We enrolled 9,967 patients in 8 provinces, 3,336 from the first and 6,631 from the second wave. Patients in the second wave were younger, fewer met criteria for severe COVID-19, and more were discharged from the Emergency Department. Adjusted for patient characteristics and disease severity, steroid use increased (odds ratio [OR] 8.0; 95% confidence interval [CI] 6.4 – 10.0), while the use of invasive mechanical ventilation decreased (OR 0.5; 95%CI 0.4 – 0.6) in the second wave. After adjusting for differences in patient characteristics and disease severity, the odds of hospitalization (OR 0.7; 95%CI 0.6 – 0.8) and critical care admission (OR 0.6; 95%CI 0.4 – 0.7) decreased, while mortality remained unchanged (OR 1.0; 95%CI 0.7-1.4).Interpretation In patients presenting to Canadian acute care facilities, rapid uptake of steroid therapy was evident. Mortality was stable despite lower critical care utilization in the second wave.Trial Registration Clinicaltrials.gov, NCT04702945Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04702945Funding StatementThe Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) and Fondation du CHU de Québec (Octroi No. 4007) provided peer-reviewed funding. The BC Academic Health Science Network and BioTalent Canada provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UBC REB: H20-01015All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe CCEDRRN network endorses the guidance put forth by the World Health Organization to enable data sharing to optimize learning. CCEDRRN accepts applications for access to data by external investigators, prioritizing data requests by network Members.